AL Amyloidosis Clinical Trial
— CArdiagOfficial title:
An Open-label, Multi-center, Non-randomized Pivotal Phase 3 Study to Evaluate the Efficacy and Safety of [18F]Florbetaben Positron Emission Tomography (PET) Imaging to Diagnose Cardiac AL Amyloidosis
This is an open-label, multi-center pivotal Phase 3 study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with suspected cardiac amyloidosis.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | June 2025 |
Est. primary completion date | March 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Males and females age =18 years - Able to understand, sign and date written informed consent - Written informed consent must be obtained before any assessment is performed - Subjects being considered for a possible diagnosis of cardiac amyloidosis by - 1. One of the following conditions: - Established systemic amyloidosis without proven cardiac involvement, - Known plasma cell dyscrasia (MGUS, multiple myeloma), - Pathological free light chain levels in urine or serum, - Presence of heart failure with preserved ejection fraction - 2. AND one of the following parameters, indicative of cardiac manifestation: - Mean (left ventricular (LV) wall + septum) thickness >12mm as measured by echocardiography in absence of other known cause of left ventricular hypertrophy (LVH), - NT-proBNP >335 ng/L - Planned diagnostic procedure to establish diagnosis and cardiac involvement (e.g., endomyocardial biopsy or extracardiac biopsy in conjunction with cardiac magnetic resonance imaging/echocardiography or bone scintigraphy) - Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for at least one week following the PET scan - Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following the PET scan - Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan Exclusion Criteria: - Any known allergic reactions or hypersensitivity towards any compound of the study drug - Severe hepatic impairment (AST/ALT >5 x ULN; bilirubin >3 x ULN) - Inability to lay flat for up to 60 min - Pregnant, lactating or breastfeeding - Unwilling and/or unable to cooperate with study procedures - Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study |
Country | Name | City | State |
---|---|---|---|
Germany | University of Augsburg | Augsburg | |
Germany | Charite Berlin | Berlin | |
Germany | University of Essen | Essen | |
Germany | HOPA Hamburg | Hamburg | |
Germany | University of Heidelberg | Heidelberg | |
Germany | University of Würzburg | Würzburg | |
Spain | Hospital University Bellvitge | Barcelona | |
Spain | Hospital University Puerta de Hierro | Madrid | |
Spain | Clínica Universidad de Navarra | Pamplona | |
Spain | University of Salamanca | Salamanca | |
United Kingdom | Royal Free Hospital | London | |
United States | St Luke's Hospital | Kansas City | Kansas |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | University of Pittsburgh | Pittsburgh | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Life Molecular Imaging GmbH | pharmtrace klinische Entwicklung GmbH |
United States, Germany, Spain, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Sensitivity and specificity of [18F]florbetaben PET images for a differential diagnosis between AL CA, ATTR CA and non CA will be assessed. | In this exploratory endpoint the sensitivity and specificity of [18F]florbetaben PET images for a differential diagnosis between AL CA, ATTR CA and non CA will be assessed. | Up to 12 weeks | |
Primary | Sensitivity and specificity of the visual assessment of [18F]florbetaben PET images for the diagnosis of cardiac AL amyloidosis. | The results from the visual assessment of [18F]florbetaben PET images are compared to the clinical diagnosis established through histological verification of the presence or absence of AL amyloidosis with cardiac involvement determined either through endomyocardial biopsy or through extracardiac biopsy in conjunction with typical CMR or echocardiography imaging features as the standard of truth. | Up to 12 weeks | |
Secondary | Sensitivity and specificity of [18F]florbetaben PET for the diagnosis of cardiac AL amyloidosis using quantification. | The sensitivity and specificity of [18F]florbetaben PET for the diagnosis of cardiac AL amyloidosis will be determined by using quantitative image analysis. | Up to 12 weeks | |
Secondary | Correlation of quantitative [18F]florbetaben PET results with left ventricular ejection fraction (LV EF) and left ventricular mass (LV mass). | Correlation of quantitative [18F]florbetaben PET results with left ventricular ejection fraction (LV EF) and left ventricular mass (LV mass). | Up to 12 weeks | |
Secondary | Correlation of quantitative [18F]florbetaben PET results with AL CA stage I - IV based on FLC-diff, cTnT and NT-proBNP levels. | Correlation of quantitative [18F]florbetaben PET results with AL CA stage I - IV based on FLC-diff, cTnT and NT-proBNP levels. | Up to 12 weeks | |
Secondary | Impact of PET imaging (AL-CA/non AL-CA) on diagnostic thinking and patient management will be assessed with physician's questionnaires before and after the diagnostic work-up, and after receipt of the PET results. | The impact of PET imaging (AL-CA/non AL-CA) on diagnostic thinking and patient management will be assessed with physician's questionnaires before and after the diagnostic work-up, and after receipt of the PET results. | Up to 14 weeks | |
Secondary | Number of adverse events | Safety will be evaluated by collection of Adverse Events. | Up to 17 days after imaging visit |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05451771 -
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
|
Phase 1/Phase 2 | |
Completed |
NCT02574676 -
Quality of Life (QOL) Registry for Patients With AL Amyloidosis
|
||
Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
Active, not recruiting |
NCT05199337 -
Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT01758042 -
Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders
|
N/A | |
Completed |
NCT01409148 -
Radioimmunoimaging of AL Amyloidosis
|
Phase 1 | |
Active, not recruiting |
NCT04512235 -
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis
|
Phase 3 | |
Not yet recruiting |
NCT06022939 -
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
|
Phase 3 | |
Recruiting |
NCT05277493 -
A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
|
||
Completed |
NCT02632786 -
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
|
Phase 2 | |
Completed |
NCT02841033 -
Daratumumab for the Treatment of Patients With AL Amyloidosis
|
Phase 1/Phase 2 | |
Completed |
NCT04304144 -
A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis
|
Phase 2 | |
Recruiting |
NCT01408225 -
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
|
||
Recruiting |
NCT04895917 -
Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis
|
Phase 2 | |
Terminated |
NCT02489500 -
Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib
|
Phase 3 | |
Completed |
NCT01570387 -
A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
|
Phase 1/Phase 2 | |
Terminated |
NCT03154047 -
Study in Subjects With Light Chain (AL) Amyloidosis
|
Phase 2 | |
Completed |
NCT03236792 -
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT04392960 -
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
|
N/A | |
Recruiting |
NCT05898646 -
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
|
Phase 2 |